Collaborations to Enhance Drug Development and Regulatory Science
ID: 351254Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$5M - $5M

Eligible Applicants

Unrestricted

Funding Category

Consumer Protection

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351254
Timeline
    Description

    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to support public-private partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The grant is particularly significant for fostering advancements in the safety, efficacy, quality, and performance of drug products. Interested applicants can apply for a funding amount of $5 million, with an expected six awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610. The opportunity is forecasted for fiscal year 2024, with no cost-sharing or matching requirements.

    Point(s) of Contact
    Terrin Brown Grantor
    (240) 402-7610
    terrin.brown@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Critical Path Public Private Partnerships Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    Reducing Fraud and Lowering Barriers to the Production of Drugs in Shortage by Outsourcing Facilities
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a federal grant titled "Reducing Fraud and Lowering Barriers to the Production of Drugs in Shortage by Outsourcing Facilities." This grant aims to enhance understanding of drug shortages, particularly those susceptible to health fraud, and to identify outsourcing facilities that can help meet these critical needs, thereby strengthening the drug supply chain. The funding, totaling $3 million with an award ceiling of $3 million and an expected two awards, will support research and development initiatives aimed at mitigating persistent drug shortages and stabilizing the supply of essential medications. Interested applicants can reach out to Patrick Johnson at patrick.johnson@fda.hhs.gov for further information, with the grant opportunity posted for the fiscal year 2025.
    Center for Research on Complex Generics (U18) Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the establishment of a Center for Research on Complex Generics through a cooperative agreement. This initiative aims to enhance collaboration with the generic drug industry, focusing on identifying scientific challenges in generic product development and facilitating research that supports the FDA's mission to improve patient access to high-quality, safe, and effective generic drugs. The Center will serve as a hub for coordination among FDA, academia, and industry stakeholders, conducting research, hosting workshops, and providing public access to research outcomes. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. The funding amount is set at $1.5 million, with one award anticipated for the fiscal year 2025.
    Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare diseases or conditions, with the goal of increasing the number of approved treatments in this area. The initiative is crucial for enhancing drug development for rare diseases, thereby potentially improving patient outcomes. Interested applicants, including higher education institutions, nonprofits, for-profit organizations, and various levels of government, can reach out to Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov or call 240-402-7610 for more information. The opportunity is currently posted for the fiscal year 2025, with no cost-sharing or matching requirements.
    Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional." This initiative aims to develop and validate an in vitro mechanistic methodology to assess the performance of amorphous solid dispersion (ASD) drug products under various clinically relevant conditions, ultimately enhancing the understanding of how food and acid-reducing agents affect drug absorption. The funding, which ranges from $250,000 to $500,000, is intended to support research that correlates in vitro observations with in vivo outcomes, thereby informing regulatory decisions for high-risk generic oral drug products. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information, with applications being accepted for the fiscal year 2024.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.
    Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is announcing a funding opportunity for a Cooperative Agreement titled "Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)." This initiative aims to support research and development of practices that mitigate risks associated with nitrosamine impurities in human drugs, thereby enhancing public health safety while ensuring access to essential therapeutic drugs. The FDA seeks to fund one award with a total funding amount of $350,000, with no cost-sharing or matching requirements. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information. The opportunity is forecasted for fiscal year 2024, and applicants may submit multiple distinct applications, adhering to guidelines regarding overlapping submissions.
    Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)" aimed at supporting innovative studies that advance medical product development for rare diseases with unmet needs. The objective of this grant is to facilitate the collection of high-quality data that addresses critical knowledge gaps and removes barriers to progress in the field of rare diseases, ultimately impacting the development of medical products. This initiative is crucial for enhancing understanding and treatment options for rare diseases, which often lack sufficient research and resources. Interested applicants can apply for funding up to $400,000, with no cost-sharing requirements, and should direct inquiries to Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov or call 240-402-7610. The opportunity is currently open and will be available for the fiscal year 2025.
    Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for applied regulatory science research aimed at evaluating and treating cardiotoxicity associated with oncology therapeutics. This initiative seeks to support research that enhances the detection, monitoring, and treatment of cardiotoxicity, with specific interests in standardizing definitions, utilizing biomarkers and imaging, and developing innovative treatment approaches. The FDA anticipates awarding two cooperative agreements under this discretionary grant, with no cost-sharing requirements, and encourages unrestricted applicants to engage in collaborative networks to share data and insights. Interested parties can contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further information, with the funding opportunity expected to be available in fiscal year 2025.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a federal grant opportunity titled "Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare neurodegenerative diseases affecting both children and adults, thereby increasing the number of approved treatments in this critical area. The initiative is part of the FDA's broader effort to enhance drug development for rare diseases, which is vital for improving health outcomes in affected populations. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for more information, with funding amounts ranging from $650,000 to $900,000 for the fiscal year 2025.